Inhibikase Therapeutics Inc. (IQT0)
XMUN 
NASDAQ (CM) Primary XMUN Summary
IQT0 Chart
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 16,041,114 shares, an increase of 52.2% from the February 12th total of 10,541,776 shares. Based on an average daily trading volume, of 3,478,233
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating and walking in a mid-stage study.
Inhibikase Therapeutics Inc. (IQT0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inhibikase Therapeutics Inc. ever had a stock split?
Inhibikase Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark T. Iwicki CEO | XMUN Exchange | US45719W2052 ISIN |
| US Country | 35 Employees | - Last Dividend | 30 Jun 2023 Last Split | 23 Dec 2020 IPO Date |
Overview
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for Parkinson's disease and related disorders. Founded in 2008 and based in Atlanta, Georgia, the company is committed to advancing its pipeline of innovative therapies. Inhibikase Therapeutics, Inc. engages in notable research and development collaborations with prestigious institutions, including Johns Hopkins University, Arizona State University, University of Bordeaux, Michigan State University, and the University of California, along with a collaborative agreement with Sphaera Pharma Pte. Ltd. These partnerships underscore the company's dedication to leveraging scientific expertise and resources to combat debilitating neurological diseases.
Products and Services
Inhibikase Therapeutics, Inc. has developed a portfolio of product candidates aimed at addressing the unmet needs of patients with Parkinson's disease and other conditions:
- IkT-148009: A leading product candidate, IkT-148009 is a small molecule inhibitor of Abelson tyrosine kinase. This compound is currently in Phase 2a clinical trials, targeting the treatment of Parkinson's disease and its manifestations in the gastrointestinal tract. The advancement of IkT-148009 represents the company's commitment to pioneering novel treatments for Parkinson's disease, focusing on one of its primary molecular targets.
- IkT-001Pro: This product is a prodrug of imatinib mesylate, a well-known anticancer agent. IkT-001Pro is being developed to treat stable phase chronic myelogenous leukemia (CML). By converting imatinib mesylate into a prodrug form, Inhibikase Therapeutics aims to improve the efficacy and safety profile of the treatment, providing an innovative approach to managing this type of leukemia.
